Individuals with a CYP2B6 reduced metabolic phenotype may have an increased risk of malaria treatment failure when treated with artemisinin derivatives48, as well as an impaired outcome of EFV or NVP-based ARTc10,29. The gene discussed is CYP2B6; the disease is malaria.